Topical Infographics US

How to Best Engage Physicians When Launching New Brands

by Mary Dominiecki, SVP, US Country Lead | Aug 19, 2022

Successful brand launches require engagement and education of the treating physicians. But how do you best engage physicians? We recently surveyed general practitioners (GPs) and specialists to ask them some pertinent questions.

Not surprisingly, interest in learning about new products is driven by potential improvements in long-term safety, efficacy, and quality of life. Lower on the list (but still important) are improvements in dosing and administration. Three-quarters of GPs (vs 55% of specialists) want to know about new products once they are approved and/or they have access. This is likely driven by the sheer volume of products and disease areas with which they need to keep track. Specialists are more likely to want to learn about a product during clinical development (44% vs 24% for GPs).

How the Pandemic Impacted New Pharma Product Launches

by Mary Dominiecki, SVP, US Country Lead | Jul 14, 2022

COVID-19 has certainly brought its challenges to all parts of our lives. We surveyed 140 US physicians (50 general practitioners (GPs) and 90 specialists to see how COVID-19 has impacted product launches. In order for product launches to be successful, treaters need to learn about the products in a timely manner and be convinced of the value they bring to them.

Roughly one-third of physicians (similar proportions of GPs and specialists) said they have initiated fewer patients on newly launched products during the pandemic. The reasons cited for this decrease include: fewer interactions with pharma, reduced patient volumes, and patient reluctance.

The Performance of Patient Support Providers During The Pandemic

by Tyler Hassman, CEO | Apr 14, 2022

We surveyed 152 physicians in the U.S. to gauge their opinions on Patient Support Program (PSPs) providers during the pandemic. Physicians surveyed include GPs, Hematologists, Medical Oncologists, Rheumatologists, Pulmonologists, Endocrinologists and Infectious Disease Specialists. Overall perceptions of PSPs compared to before the pandemic have generally improved – especially in terms of responsiveness and the expertise of individuals working on PSPs.

Pandemic Impact On Patient Support Programs

by Tyler Hassman, CEO | Mar 23, 2022

PSPs play a significant role in ensuring that patients have the best possible experience during their journey – especially in specialty therapeutic areas where treatments tend to be more expensive. The pandemic has made it more challenging for patients to access support and services for their medical conditions. This has put additional pressure on company-sponsored PSPs to further enhance their offerings to help patients in the best way possible.

PSPs have become increasingly important for patients since the onset of the COVID-19 pandemic and as a result now have an even more significant influence on physicians’ treatment selection process. For the most part, physicians acknowledge that PSP providers have adjusted well to the new reality brought forth by COVID-19. About a third even think that PSP providers have improved their performance since the onset of the pandemic.

In-person Interactions With Pharma Will Return

by Tyler Hassman, CEO | Nov 25, 2021

While the vaccination campaign in the U.S. is progressing, COVID-19 continues to significantly impact healthcare practices. As knowledge about the virus evolved during the pandemic, physicians and other HCPs have continuously adapted how they manage their patients and how they interact with key stakeholders. Half of the physicians surveyed expect to see increased workloads as 2021 draws to a close. Patient volumes continue to inch closer to pre-pandemic levels and requests for diagnostic testing along with treatment switches have now exceeded pre-pandemic levels.

MD Analytics has been monitoring these trends and we are excited to share with you our new downloadable infographic on this topic.

How COVID-19 is affecting HCPs as vaccinations take hold

by Tyler Hassman, CEO | Aug 25, 2021

As the COVID-19 vaccination campaign ramped up in the Spring, and rates of infection dropped, a return to normality appeared to be on the horizon. However, with widespread vaccine hesitancy paired with the virulent spread of the delta variant, we are once again left with an uncertain view of the future.

Throughout the past year, MD Analytics has been monitoring the effects of this uncertainty, and the pandemic in general, on the practices and perceptions of HCPs. Ongoing changes in workloads, patient assessments, and interactions with pharma have had direct and meaningful impact on the healthcare industry.

Remote detailing for pharma – Physicians’ perspectives

by Tyler Hassman, CEO | Mar 12, 2021

The detailing of healthcare providers through virtual means has become a staple for pharmaceutical brands and is essential for any go-to-market strategy. When face-to-face detailing was put on hold this past year, healthcare providers began experiencing an even greater volume of requests for virtual interactions. For pharma brand teams, ensuring your approach to digital communications matches with the preferences of providers is important in helping your messages get through to your target prescribers.

In our latest quick poll, conducted in March 2021, MD Analytics sought to gain clarity around current remote detailing preferences and identify the components of an “ideal” remote interaction.

The Future of Medical Conferences is Virtual

by Tyler Hassman, CEO | Jan 21, 2021

Each year, providers and health industry professionals travel from locations around the world to share and discuss the latest developments in medical care. For several years now, conferences have been experimenting with digital features that allow participants to engage remotely, avoiding the burdens of travel. However, the scope of content available to digital participants had often been limited and physician adoption was low.

We are here to answer your questions.